Skip to main content

Table 2 Predictors of reduced left ventricular ejection fraction during study follow-up

From: Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study

  Univariate Model 1 Model 2 Model 3
Female sex 0.31 (0.01-1.01) 0.23 (0.06-0.95) 0.35 (0.07-1.70)
Age 1.04 (1.00-1.08) 1.06 (1.01-1.11) 1.07 (1.01-1.13)
Basal LVEF 1.16 (1.08-1.25) 1.16 (1.08-1.25) 1.16 (1.07-1.25)
Basal hsCRP (Q4 vs Q1) 2.11 (0.68-6.51) 4.74 (1.03-21.8) 3.52 (0.73-17.1) 5.30 (0.04-659)
Basal PCSK9 (Q4 vs Q1) 0.85 (0.28-2.61) 1.88 (0.40-8.83) 2.63 (0.47-14.7) 17.1 (1.48-198)
Basal NT-proBNP (Q4 vs Q1) 1.26 (0.36-4.42) 0.84 (0.19-3.80) 0.83 (0.16-4.25) 0.63 (0.11-3.77)
Basal FABP3 (Q4 vs Q1) 1.45 (0.44-4.71) 2.33 (0.55-9.94) 1.82 (0.34-9.81) 2.67 (0.38-18.5)
  1. Data are OR (95% CI). For biomarkers, the lowest quartile of plasma concentration was used as reference group. LVEF Left ventricular ejection fraction, hsCRP High-sensitivity C-reactive protein, PCSK9 Proprotein convertase subtilisin kexin 9, NT-proBNP N-terminal prohormone of brain natriuretic peptide, FABP3 Heart-type fatty acid binding protein. Model 1 includes sex, age and baseline LVEF as independent variables. Model 2 includes all variables in Model 1 plus number of obstructed coronary vessels and percent maximal coronary obstruction. Model 3 includes all variables in model 2 plus change in the respective biomarker (final-basal plasma concentration)